As previously reported, Evercore ISI analyst Steven Breazzano upgraded Clovis (CLVS) and Tesaro (TSRO), both to Outperform from In Line, as he believes the stocks' valuations are now attractive on a long-term basis following their pullbacks. He views adoption of the PARP class so far as robust, particularly in ovarian cancer, and sees further upside as PARPs move up into earlier lines of therapy, combination studies, and new indications. However, Breazzano lowered his price target on Clovis shares to $72 from $73 and decreased his target on Tesaro to $88 from $121.